**
Recent research has revealed that obstructive sleep apnoea (OSA), a condition that causes individuals to intermittently stop breathing during sleep, imposes a staggering economic burden of over £137 billion ($185 billion) annually on both the UK and US economies. Characterised by loud snoring and severe daytime fatigue, this condition is not only detrimental to individual health but also poses significant risks for heart attack and stroke. Alarmingly, many who suffer from OSA remain undiagnosed, highlighting a pressing need for increased awareness and intervention.
Understanding Obstructive Sleep Apnoea
OSA affects approximately one billion people worldwide, with about eight million in the UK alone. According to a study conducted by researchers at University College London, nearly 20% of surveyed adults reported experiencing breathing interruptions during sleep alongside excessive daytime sleepiness—two critical indicators of this condition. Despite the prevalence of OSA, a staggering 85% of those affected are unaware they have it, underscoring the urgent need for improved diagnostic measures.
The study’s findings, published in the journal *Thorax*, indicate that OSA leads to significant productivity losses due to absenteeism and impaired performance at work. Researchers estimated that the economic impact on the US alone amounts to $180 billion (£133 billion), while the UK bears a burden of £4.2 billion annually. These figures likely underestimate the true cost, as they do not account for increased healthcare expenses or the potential for accidents on the road or in the workplace resulting from untreated sleep apnoea.
The Call for Action
The authors of the study advocate for proactive measures to address the growing concern of sleep apnoea. They urge policymakers to prioritise the development of effective screening strategies and targeted public health campaigns. “Given the significant yet often overlooked burden of obstructive sleep apnoea and its economic impact, we encourage the allocation of resources towards early identification and treatment,” the researchers stated. They believe that timely intervention could lead to substantial savings, potentially amounting to billions in productivity costs annually.
While advancements in technology and screening protocols could facilitate easier diagnosis of OSA, maintaining effective treatment poses its own challenges. Continuous positive airway pressure (CPAP) therapy is the standard treatment for OSA, yet nearly two-thirds of patients discontinue its use. Alternative treatments, such as weight loss medications, oral appliances, and hypoglossal nerve stimulation, are not universally applicable, leaving many without viable options.
Concerns About Stigma and Employment
The potential stigma surrounding OSA diagnosis is another barrier to effective treatment. Many individuals, particularly those in professional driving roles, may hesitate to seek help due to fears of job loss. Adrian Jones, national officer at the trade union Unite, commented on this issue, stating, “Professional drivers often hide issues of sleep apnoea out of fear of losing their jobs.” He emphasised the need for educational initiatives for employers, ensuring they understand that sleep apnoea can be effectively managed. Workers must feel secure that they will receive support rather than face dismissal if a diagnosis is made.
Why it Matters
The implications of untreated obstructive sleep apnoea extend far beyond individual health; they ripple through our economy and society. With billions lost to decreased productivity and increased healthcare costs, the need for comprehensive screening and treatment strategies is paramount. Addressing this widespread yet often ignored condition can lead to healthier lives for millions and a more robust economy for all. It is a collective responsibility to ensure that those suffering from sleep apnoea are identified, treated, and supported, paving the way for a healthier future.
